Researchers discovered that an immunotherapy, called anti-CTLA-4, mobilizes microglia against glioblastoma as it causes CD4+ T cell infiltration of the brain. A study led by Salk Institute (CA, USA) ...

Students who formed an encampment at Columbia University in New York City, in protest of Israel’s war against Hamas in Gaza, were met with the full force of the New York Police Department after ...

Students at Columbia University were told in an overnight statement that all classes will be held virtually on Monday as anti-Israel protesters have taken over the campus, its president announced ...

From Harvard and Penn to Yale and Columbia, antisemitism at many Ivy League universities is worsening with some pro-Palestinian protesters deliberately aiming to disrupt life on both campus and ...

Xilio is building a pipeline of wholly-owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody ...

The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4 ...

Short for strategic lawsuits against public participation, SLAPPs have become an all-too-common tool for intimidating and silencing criticism through expensive, baseless legal proceedings. Anti-SLAPP ...

But the real advance has been the combinations with immune therapies—the anti–PD-1 and PD-L1 strategies or the combinations of anti–PD-1 and anti–CTLA-4. These have obviously increased ...

ONC-841 is a potential first-in-class SIGLEC 10 antibody designed to block an innate and potentially adaptive immune ...

announces that the first participant has been successfully dosed with IBI310 (anti-CTLA-4 monoclonal antibody) in combination with sintilimab (PD-1 inhibitor) in a randomized, controlled ...

In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 ...